Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Ube3a-ubiquitinated protein phosphatase 2A (PP2A) activating factor, namely tyrosine phosphatase activating factor (PTPA), for treating Angelman syndrome and autism

A technology for syndromes and activating factors, applied in the fields of molecular biology and pharmacology, can solve problems that cannot explain neurodevelopmental disease phenotypes well

Active Publication Date: 2019-09-17
CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although some substrates of Ube3a have been reported, none of these substrates can well explain the phenotype of neurodevelopmental diseases caused by Ube3a abnormalities, and there is no effective drug treatment to intervene in the abnormality of the gene segment where Ube3a is located. disease caused by

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Ube3a-ubiquitinated protein phosphatase 2A (PP2A) activating factor, namely tyrosine phosphatase activating factor (PTPA), for treating Angelman syndrome and autism
  • Application of Ube3a-ubiquitinated protein phosphatase 2A (PP2A) activating factor, namely tyrosine phosphatase activating factor (PTPA), for treating Angelman syndrome and autism
  • Application of Ube3a-ubiquitinated protein phosphatase 2A (PP2A) activating factor, namely tyrosine phosphatase activating factor (PTPA), for treating Angelman syndrome and autism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0318] Example 1, Detection of PTPA protein level in Ube3a deficient mice

[0319] First, 30-day-old (P30) mice were taken out: wild-type (WT) and littermate AS mice with maternal deletion of Ube3a (obtained from Duke University, a termination was introduced under exon 2 of Ube3a codon, resulting in the non-expression of Ube3a), anesthetized, and injected 0.7% sodium pentobarbital intraperitoneally according to the standard of 70mg / kg; Put it into pre-cooled 0.9% normal saline, wash away the blood with normal saline, put it on sterile filter paper, use tweezers and hippocampal spoon to dissect the brain tissue, put half of the cerebellum tissue into a 2ml Axygen centrifuge tube, and then Put 400ul of RIPA lysate with 1mM PMSF into it, put a 3mm diameter magnetic bead into a tissue homogenizer, break it at 60Hz for 30s, take it out, and put it on ice for 30min. Afterwards, in a refrigerated centrifuge at 4°C, centrifuge at 14000 g for 20 min, then take the supernatant into a n...

Embodiment 2

[0339] Example 2, UBE3A ubiquitination of PTPA

[0340] 1) GST pull-down

[0341] Purification of GST-tagged protein: The constructed prokaryotic expression plasmid (PGEX-4T-1 or Pgex-4T-1-UBE3A) was transformed into a competent Rosetta expression strain, and spread on an ampicillin-resistant plate. After the colonies grow out, pick the colonies and place them in 5 mL of LB bacterial culture medium containing antibiotics, culture them overnight at 37 degrees Celsius and 250 rpm. The overnight cultured bacteria were inserted into the LB bacterial medium to which antibiotics had been added at a ratio of 1:100, and cultured at 37°C until OD600=0.6-0.8 (about 2.5 hours). Then add IPTG (0.168mM) and induce for 5 hours at 27°C. The induced bacterial liquid was centrifuged at 12000rpm for 2 minutes and collected into a 15mL centrifuge tube. Add 5 mL of GST lysis buffer (PBS+1% TritonX-100, 1 mM PMSF) to resuspend the cells. Ultrasonic at 80-100W for 5 seconds, with an interval of...

Embodiment 3

[0350] Example 3, Detection of PP2A activity in Ube3a deficient mice

[0351] The whole brain of the mouse was taken out according to the method in Example 1, it was put into a pre-cooled glass homogenizer, and 1ml of imidazole lysate (20mM imidazole hydrochloride (PH7.0), 2mM EDTA, 2mM EGTA, 1mM PMSF , 5ul Protease Inhibitor Cocktail (P8430)), homogenate about 20 times, transfer the lysate to a 1.5ml centrifuge tube with a pipette, and insert it into an ice box. Put the centrifuge tube into a refrigerated centrifuge, centrifuge at 3000g for 5min at 4°C. Take out the supernatant into a new centrifuge tube, and measure the protein concentration according to the method in Example 1.

[0352]Take 500ug of protein into a new 1.5ml centrifuge tube, make up the volume to 500ul with imidazole lysate, and complete the detection of PP2A activity according to the steps provided by the PP2A activity detection kit (Moker Millipore, #17-313). Specifically, 4ug of Anti i-PP2A, C (#05-421)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of an Ube3a-ubiquitinated protein phosphatase 2A (PP2A) activating factor, namely a tyrosine phosphatase activating factor (PTPA), for treating Angelman syndrome and autism. The invention discloses new pathogenesis of Angelman syndrome and / or autism or other related diseases; that is to say, lack or over-expression of Ube3a results in abnormal activity of the tyrosine phosphatase activating factor (PTPA) on the protein phosphatase 2A (PP2A). Thus, the factors can be used as targets for developing drugs to alleviate or treat Angelman syndrome and / or autism or other related diseases. The factors can also be used as markers for diagnosing and assessing Angelman syndrome and / or autism or other related diseases.

Description

technical field [0001] The invention belongs to the fields of molecular biology and pharmacy, and more specifically, the invention relates to Ube3a regulating the activity of PP2A and its application in treating Angelman syndrome and autism. Background technique [0002] The UBE3A gene is located in the 15q11-13 region of human chromosome 15, and its encoded product Ube3a is the first E3 ubiquitin ligase found in the HECT (Homologous with E6-assiciated protein C-Terminus) family. Because there is an E6-binding domain in its protein structure, it is also called E6AP. So far, Ube3a has two functions: one is as an E3 ligase, which mediates the ubiquitination modification of the specific substrate it recognizes, and then regulates protein degradation, transportation, localization, etc.; the other is in the nucleus, Ube3a can Binds to hormone receptors and acts as an activator to regulate gene transcription. [0003] In neurons, Ube3a specifically expresses maternally derived g...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P43/00A61P25/28A61P25/14C12Q1/42C12Q1/6883
CPCA61K45/00A61P43/00A61P25/28A61P25/14C12Q1/42C12Q1/6883C12Q2600/118
Inventor 熊志奇王杰
Owner CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com